IPP Bureau
Reliance Life Science gets go-ahead for Phase I clinical trial for Covid-19 vaccine
By IPP Bureau - September 04, 2021
The trial will be conducted across eight sites in Maharashtra
Indian Railways to deploy HMIS across its network
By IPP Bureau - September 04, 2021
Implementation of the system to provide faster, seamless and hassle-free healthcare solutions
Dr Reddy’s enters agreement with Citius to sell rights of its anti-cancer agent
By IPP Bureau - September 04, 2021
In March 2016, Dr. Reddy’s had acquired the exclusive global rights (excluding Japan and Asia) to the investigational anti-cancer agent E7777 from Eisai Co.
DGCI green lights Biological E for Phase 2/3 trials of its Covid-19 vaccine candidate for children
By IPP Bureau - September 03, 2021
The trial will be conducted across 10 sites in India
Indigenous technology will help reduce dependence on imports: Dr Singh
By IPP Bureau - September 03, 2021
Union Minister addresses the 13th CII Global MedTech Summit on the sunrise medical devices sector in India
Omeza Collegen Matrix gets U.S. FDA approval
By IPP Bureau - September 03, 2021
This is Omeza’s first Rx product and the first drug/device combination matrix of its kind for chronic wound care
Pfizer announces Phase 3 clinical trial for vaccine against Respiratory Syncytial Virus (RSV)
By IPP Bureau - September 03, 2021
RSV is a common and pervasive cause of severe acute respiratory illness in older adults with no vaccine currently available
Covid-19 vaccine clinical trial for people with autoimmune disease
By IPP Bureau - September 03, 2021
Researchers at the Feinstein Institutes administer extra vaccine doses as part of the NIH funded study
Novartis signs world’s first agreement with NHS, UK
By IPP Bureau - September 03, 2021
The agreement follows positive NICE recommendation and commits to deliver Leqvio (inclisiran) access via a population health management approach identifying eligible patients across England
CII awards Excellence in Energy efficiency to Sai Life Sciences API unit
By IPP Bureau - September 03, 2021
The Bidar API manufacturing facility of Sai Life Sciences has been on a path of significant expansion with its production capacity growing from 200KL in 2017 to 450KL
Digital adoption in healthcare will see exponential growth: Wipro GE study
By IPP Bureau - September 03, 2021
Key trends indicate that AI-based solutions, cloud-based healthcare solutions and digital transformations will be the key in the years to come.
Phase 2 of Covaxin intranasal trials begin in Kanpur
By IPP Bureau - September 02, 2021
The vaccine is designed to neutralise the virus in the nostril itself and prevent it from penetrating deep down into the respiratory tract
Natco Pharma launch Nat-Lenalidomide in Canada
By IPP Bureau - September 02, 2021
Nat-Lenalidomide, a generic alternative to Revlimid, expands affordable treatment options for patients with multiple myeloma and patients with transfusion-dependent anaemia due to myelodysplastic syndromes (MDS)
Reddy-Lenalidomide launched in Canada
By IPP Bureau - September 02, 2021
Dr. Reddy's Laboratories Canada announces the launch of Reddy-Lenalidomide, one of the first generic medications of its kind for the Canadian market
Sun Pharma Industries announce sale of Kayaku
By IPP Bureau - September 02, 2021
The company has been sold to Shinshin Pharmaceuticals
